Evidence map›Paper›PMID 26379915›Full record

ArticleInternational journal of clinical and experimental medicine2015

Analysis of different fractionations of three-dimensional conformable radiotherapy for esophageal cancer.

Zhiqian Ma, Yan Zhang, Xiaofang Chen, Chaoxing Liu, Huijun Xu, Peng Zhao

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Zhiqian MaDepartment of Radiation Oncology, The First Hospital of Shijiazhuang City Shijiazhuang 050011, Hebei Province, China.
Yan ZhangDepartment of Radiation Oncology, The First Hospital of Shijiazhuang City Shijiazhuang 050011, Hebei Province, China.
Xiaofang ChenDepartment of Radiation Oncology, The First Hospital of Shijiazhuang City Shijiazhuang 050011, Hebei Province, China.
Chaoxing LiuDepartment of Radiation Oncology, The First Hospital of Shijiazhuang City Shijiazhuang 050011, Hebei Province, China.
Huijun XuDepartment of Radiation Oncology, The First Hospital of Shijiazhuang City Shijiazhuang 050011, Hebei Province, China.
Peng ZhaoDepartment of Radiation Oncology, The First Hospital of Shijiazhuang City Shijiazhuang 050011, Hebei Province, China.
First Hospital of Shijiazhuang · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to observe and discuss the curative and side effects of three different fractionation regimen of three-dimensional conformable radiotherapy (3DCRT) for esophageal cancer. A total of 169 untreated patients of esophageal cancer were randomized into three groups: groups A (conventional group, 2.0 Gy per time), B (2.5 Gy group, 2 Gy per time), and C (3.0 Gy group, 3.0 Gy per time), respectively. Groups A, B, and C are similar in terms of partial response (P = 0.35). However, the three groups had no significant differences in terms of the complete response (P = 0.63). The three-year survival rate of group B was higher than those of the other two groups, and the difference was significant (P = 0.047). For the three-year local control rate, that of group B was also higher than those of groups A and C, but the difference was not significant (P = 0.067). The incidence rate of 3 level esophagitis and bronchitis was highest in group C (P = 0.023 and P = 0.064). The 3 level tardive radioactive esophagitis in group C was higher than those in other two groups (P = 0.037 and P = 0.04). The incidence rate of the 3 level advanced lung reaction was also the highest in the three groups (P = 0.041). The effect is better and the side effect is tolerable for the 2.5 Gy per fraction, 5 times per week; thus, it can be used clinically for 3DCRT for esophageal carcinoma.

Indexed as

Carcinomaesophageal/radiotherapyfractionationradiotherapythree-dimensional conformal

Identifiers

PMID26379915
PMCPMC4565298
OpenAlexW2435643106

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.